T. Rowe Price reports 4.3% MediWound stake

T. Rowe Price Associates, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 554,498 shares of MediWound Ltd. common stock, representing 4.3% of the class as of the event date.

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed an amended Schedule 13G/A reporting its beneficial ownership of 554,498 shares of MediWound Ltd. common stock, representing 4.3% of the class as of the event date. The firm has sole voting power over 535,181 shares and sole dispositive power over 554,498 shares, with no shared voting or dispositive power. The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of MediWound. T. Rowe Price Associates also affirms that the filing should not be construed as an admission that it is the beneficial owner of these securities.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does T. Rowe Price Associates report in this MediWound (MDWD) Schedule 13G/A?

T. Rowe Price Associates reports beneficial ownership of 554,498 shares of MediWound common stock. This holding represents 4.3% of the outstanding class and is reported on an amended Schedule 13G/A as of the specified event date.

How large is T. Rowe Price Associates’ ownership stake in MediWound (MDWD)?

T. Rowe Price Associates reports beneficial ownership of 554,498 MediWound common shares, equal to 4.3% of the class. This percentage indicates they hold less than 5% of outstanding shares, which is a common disclosure threshold for institutional investors.

What voting and dispositive powers does T. Rowe Price Associates have over MediWound (MDWD) shares?

The firm reports sole voting power over 535,181 MediWound shares and sole dispositive power over 554,498 shares. It reports no shared voting or dispositive power, meaning decisions over these shares are controlled solely by T. Rowe Price Associates under this filing.

Is T. Rowe Price Associates seeking to influence control of MediWound (MDWD)?

The filing states the MediWound securities were acquired and are held in the ordinary course of business. It explicitly notes they were not acquired and are not held to change or influence control of MediWound, nor as part of a control-related transaction.

Why does the MediWound (MDWD) filing mention ownership of 5 percent or less of a class?

Item 5 confirms that T. Rowe Price Associates’ MediWound holdings represent 5 percent or less of the outstanding class. This disclosure indicates the position is below a key regulatory threshold for larger beneficial ownership and aligns with Schedule 13G reporting requirements.

Does T. Rowe Price Associates admit beneficial ownership of the MediWound (MDWD) shares?

The firm expressly states the filing should not be construed as an admission that it is the beneficial owner of the MediWound securities. It declares and affirms that such beneficial ownership is denied, while still reporting the position for regulatory purposes.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/17/2026 - 10:26 AM Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 1)

MEDIWOUND LTD

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

M68830112

(CUSIP Number)

12/31/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. M68830112

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 535,181.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 554,498.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

554,498.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

4.3 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: MEDIWOUND LTD
(b)	Address of issuer's principal executive offices: 42 HAYARKON STREET, YAVNE, L3, 8122745
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: M68830112
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 554498
(b)	Percent of class: 4.3 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 535181
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 554498
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	02/17/2026